. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430

Table 2. Focused miRNA panel – miRNAs significantly associated with time to disease progression.

	Screening CAPEOXBEV cohort			Validation CAPEOXBEV cohort			Combined CAPEOXBEV cohort			Control CAPEOX cohort			Interaction^a
	n = 155			n = 121			n = 276			n = 127			all	distal	proximal
miRNA	HR^b	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	P	P	P
Raw expression values
miR-15a-5p	0.88	0.73–1.06	0.19	0.73	0.54–0.98	0.04	0.86	0.73–1.00	0.05	1.03	0.80–1.31	0.84	0.14	0.25	0.15
miR-17-3p	0.68	0.54–0.84	0.0005	0.92	0.68–1.23	0.57	0.77	0.64–0.91	0.003	1.01	0.78–1.31	0.92	0.16	0.11	0.67
miR-193b-5p	0.82	0.70–0.95	0.01	0.74	0.54–1.01	0.06	0.82	0.72–0.94	0.004	0.92	0.77–1.10	0.34	–^c	–	–
miR-204-5p	0.83	0.71–0.96	0.02	0.92	0.68–1.23	0.56	0.83	0.71–0.97	0.02	0.90	0.71–1.14	0.38	0.86	0.60	0.25
miR-501-5p	0.78	0.63–0.97	0.03	0.88	0.63–1.23	0.46	0.81	0.66–0.99	0.04	0.96	0.69–1.32	0.78	0.48	0.47	0.84
miR-545-3p	0.87	0.77–1.00	0.04	0.87	0.73–1.05	0.15	0.86	0.77–0.96	0.005	1.00	0.88–1.14	0.97	0.11	0.17	0.29
miR-592	0.71	0.54–0.93	0.01	0.80	0.62–1.01	0.06	0.77	0.67–0.90	0.0007	0.81	0.58–1.12	0.21	0.14	0.11	0.82
miR-664-3p	0.87	0.66–1.15	0.32	0.60	0.41–0.87	0.007	0.80	0.65–0.99	0.04	0.81	0.58–1.13	0.21	0.10	0.04	0.31
Mean-normalized expression values
miR-17-3p	0.78	0.63–0.98	0.03	1.05	0.83–1.34	0.68	0.89	0.76–1.05	0.16	1.10	0.82–1.48	0.52	0.22	0.09	0.26
miR-155-5p	1.36	1.07–1.71	0.01	1.33	1.00–1.77	0.05	1.38	1.15–1.64	0.0005	1.05	0.79–1.38	0.74	0.05	0.18	0.18
miR-185-5p	1.45	1.17–1.80	0.0008	1.23	0.87–1.74	0.24	1.30	1.10–1.54	0.003	0.89	0.67–1.19	0.44	0.06	0.20	0.43
miR-204-5p	0.82	0.68–0.98	0.03	1.13	0.87–1.46	0.38	0.90	0.78–1.03	0.13	0.95	0.79–1.13	0.54	0.15	0.07	0.14
miR-449a	1.25	1.03–1.52	0.02	0.97	0.73–1.28	0.81	1.15	0.99–1.35	0.07	1.00	0.80–1.26	0.96	0.55	0.89	0.74

Interaction tests were performed for all patients and for patients with distal (sigmoid and rectum) and proximal (cecum to descending) primary tumor location, separately.

Hazard ratio is per inter-quartile range expression increase and is adjusted for age, sex, number of metastatic sites, prior adjuvant treatment and primary tumor location.

miRNA was missing in >10% of samples so interaction was not tested.

Abbreviations: HR, hazard ratio; CI, confidence interval.